Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Jeffry K. Smith who wrote (2674)	12/18/2010 5:14:58 PM
From: tuck	2 Recommendations Read Replies (1) \| Respond to of 3027

Based on the latest statements from Teva, it seems it is hung up on immunogenicity issues, as opposed to failure to meet the 5 criteria. But some feel that Teva has left enough wiggle room in their statements about meeting the 5 criteria, that that may still be an issue. Failure to meet the immunogenicity standard might imply failure to meet one of the 5 criteria, as well. In spite of Teva's contentions and posturing, I think thy will not get approved, and that they will continue to posture and push out the timeline on a quarterly basis, while implicitly, if not overtly, blaming it on the intransigence of the FDA. Their 'tude suggests that they are not trying to advance development of t-enox, but are sticking with what they've got -- whatever it is -- and hoping for the regulatory best. I wonder how much longer their credibility on this issue will last. I think the most pessimistic analysts (except Oppenheimer, which seems to be in the "not approved for a long time if ever" camp already) are expecting approval in the first half of next year. So if it doesn't happen, I would expect the overhang to finally start lifting. Cheers, Tuck